Evaluation of the Success of Artificial Intelligence Models in Interpreting Arterial Waveform Analysis Data

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorKanuni Sultan Suleyman Training and Research Hospital

About this trial

The goal of this observational study is to evaluate the ability of artificial intelligence (AI) models to interpret arterial waveform analysis data obtained from a hemodynamic monitoring system in adult patients undergoing elective surgery. The main questions it aims to answer are:

Can AI models (ChatGPT-4 and Gemini 2.0) accurately detect hemodynamic abnormalities in arterial waveform data? How well do AI-generated diagnoses align with expert anesthesiologist assessments? Are AI-generated treatment recommendations clinically appropriate?

Participants will:

Undergo standard hemodynamic monitoring with an arterial waveform analysis device (MostCare).

Have their anonymized hemodynamic data analyzed by AI models for abnormality detection, diagnosis suggestions, and treatment recommendations.

Have AI-generated results reviewed and validated by experienced anesthesiologists.

This study aims to assess whether AI models can serve as decision-support tools in perioperative and critical care settings by improving the interpretation of complex hemodynamic data, potentially enhancing patient safety, diagnostic accuracy, and clinical efficiency.

Eligibility criteria

Qualifiers

Age ≥ 18 years

Undergoing elective surgery with arterial waveform monitoring as part of standard perioperative care

Hemodynamic data successfully recorded using the MostCare hemodynamic monitoring system

Able to provide informed consent to participate in the study

Disqualifiers

Incomplete or corrupted hemodynamic data (e.g., signal artifacts preventing reliable analysis)

Emergency surgery cases

Patients with severe arrhythmias or hemodynamic instability that might interfere with arterial waveform interpretation

Refusal to participate or withdrawal of consent

Trial design

Treatments tested in this trial

  • predictions

Treatment groups

No treatment groups listed